| Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer EC Dijkers, TH Oude Munnink, JG Kosterink, AH Brouwers, PL Jager, ... Clinical Pharmacology & Therapeutics 87 (5), 586-592, 2010 | 878 | 2010 |
| 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer F Bensch, EL van der Veen, MN Lub-de Hooge, A Jorritsma-Smit, ... Nature medicine 24 (12), 1852-1858, 2018 | 570 | 2018 |
| Indium-111–labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer PJ Perik, MN Lub-De Hooge, JA Gietema, WTA van der Graaf, ... Journal of clinical oncology 24 (15), 2276-2282, 2006 | 440 | 2006 |
| In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft WB Nagengast, EG De Vries, GA Hospers, NH Mulder, JR De Jong, ... Journal of Nuclear Medicine 48 (8), 1313-1319, 2007 | 426 | 2007 |
| Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging ECF Dijkers, JGW Kosterink, AP Rademaker, LR Perk, ... Journal of nuclear medicine 50 (6), 974-981, 2009 | 404 | 2009 |
| Immuno-PET: a navigator in monoclonal antibody development and applications GAMS Van Dongen, GWM Visser, MN Lub-de Hooge, EG De Vries, ... The oncologist 12 (12), 1379-1389, 2007 | 400 | 2007 |
| Preclinical characterisation of 111In‐DTPA‐trastuzumab MN Lub‐de Hooge, JGW Kosterink, PJ Perik, H Nijnuis, L Tran, J Bart, ... British journal of pharmacology 143 (1), 99-106, 2004 | 301 | 2004 |
| Tumor-specific uptake of fluorescent bevacizumab–IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study LE Lamberts, M Koch, JS de Jong, ALL Adams, J Glatz, MEG Kranendonk, ... Clinical Cancer Research 23 (11), 2730-2741, 2017 | 260 | 2017 |
| A review of bispecific antibodies and antibody constructs in oncology and clinical challenges FV Suurs, MN Lub-de Hooge, EGE de Vries, DJA de Groot Pharmacology & therapeutics 201, 103-119, 2019 | 256 | 2019 |
| 89Zr-bevacizumab PET imaging in primary breast cancer SBM Gaykema, AH Brouwers, MN Lub-de Hooge, RG Pleijhuis, ... Journal of nuclear medicine 54 (7), 1014-1018, 2013 | 200 | 2013 |
| Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis BPC Hazenberg, MH van Rijswijk, DA Piers, MN Lub-de Hooge, ... The American journal of medicine 119 (4), 355. e15-355. e24, 2006 | 188 | 2006 |
| 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to … MA De Korte, EGE De Vries, MN Lub-de Hooge, PL Jager, JA Gietema, ... European Journal of Cancer 43 (14), 2046-2051, 2007 | 174 | 2007 |
| 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922 WB Nagengast, MA de Korte, THO Munnink, H Timmer-Bosscha, ... Journal of Nuclear Medicine 51 (5), 761-767, 2010 | 163 | 2010 |
| Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery M Kijanka, FJ Warnders, M El Khattabi, M Lub-de Hooge, GM van Dam, ... European journal of nuclear medicine and molecular imaging 40, 1718-1729, 2013 | 162 | 2013 |
| 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients SBM Gaykema, CP Schröder, J Vitfell-Rasmussen, S Chua, ... Clinical Cancer Research 20 (15), 3945-3954, 2014 | 141 | 2014 |
| VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment WB Nagengast, MN Lub-de Hooge, SF Oosting, WFA den Dunnen, ... Cancer research 71 (1), 143-153, 2011 | 140 | 2011 |
| 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment SF Oosting, AH Brouwers, SC van Es, WB Nagengast, THO Munnink, ... Journal of Nuclear Medicine 56 (1), 63-69, 2015 | 137 | 2015 |
| Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake M Arjaans, TH Oude Munnink, SF Oosting, ... Cancer research 73 (11), 3347-3355, 2013 | 136 | 2013 |
| Antibody positron emission tomography imaging in anticancer drug development LE Lamberts, SP Williams, AGT Terwisscha van Scheltinga, ... Journal of Clinical Oncology 33 (13), 1491-1504, 2015 | 127 | 2015 |
| Molecular imaging of breast cancer THO Munnink, WB Nagengast, AH Brouwers, CP Schröder, GA Hospers, ... The Breast 18, S66-S73, 2009 | 123 | 2009 |
